Huadong Medicine Co, Ltd is a pharmaceutical company based in China, specializing in the production and sales of antibiotics, Chinese medicine, chemical synthetic medicine, and genetic engineering drugs. They also deal in wholesale, retail, and distribution of a wide range of healthcare products. With an ESG risk rating score of 38.1, the company is classified as high risk. Their product portfolio includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and more.